Clinical Scorecard: Molecular Subtypes and Biomarkers of Advanced Cutaneous T-Cell Lymphoma Identified Through Proteomic and Transcriptomic Analyses

At a Glance

Key Highlights

• Three molecular subtypes of advanced CTCL identified: intracellular signaling, metabolic, and extracellular matrix remodeling.
• PI3K-AKT-mTOR pathway upregulated in the intracellular signaling subtype.
• Potential biomarkers for treatment responsiveness include CTSB, GSTO1, and WDFY4.
• GOLGA1 and STIP1 identified as potential biomarkers for disease progression.
• Study highlights interpatient heterogeneity in treatment response and prognosis.

Guideline-Based Recommendations

Diagnosis

• Utilize proteomic and transcriptomic profiling for characterizing advanced CTCL.

Management

• Consider PI3K inhibitors for patients with upregulated phospho-AKT.

Monitoring & Follow-up

• Monitor expression levels of identified biomarkers for treatment response and progression.

Risks

• Advanced-stage CTCL poses significant challenges in clinical management due to variable treatment responses.

Patient & Prescribing Data

Patients with advanced-stage CTCL, particularly those with aggressive disease manifestations.

Therapeutic options include interferon, oral methotrexate, oral retinoids, histone deacetylase inhibitors, brentuximab vedotin, mogamulizumab, and PI3K inhibitors.

Clinical Best Practices

• Implement risk stratification based on treatment responsiveness and progression risk.
• Validate biomarkers in larger cohorts to enhance clinical decision-making.

Related Resources & Content